Objective-The objective of this study is to evaluate whether exogenously induced hyperinsulinemia may increase the development of atherosclerosis. Approach and Results-Hyperinsulinemia, induced by exogenous insulin implantation in high-fat fed (60% fat HFD) apolipoprotein E-deficient mice (ApoE −/− ) mice, exhibited insulin resistance, hyperglycemia, and hyperinsulinemia. Atherosclerosis was measured by the accumulation of fat, macrophage, and extracellular matrix in the aorta. After 8 weeks on HFD, ApoE −/− mice were subcutaneously implanted with control (sham) or insulin pellet, and phlorizin, a sodium glucose cotransporters inhibitor (1/2)inhibitor, for additional 8 weeks. Intraperitoneal glucose tolerance test showed that plasma glucose levels were lower and insulin and IGF-1 (insulin-like growth factor-1) levels were 5.3-and 3.3-fold higher, respectively, in insulin-implanted compared with sham-treated ApoE −/− mice. Plasma triglyceride, cholesterol, and lipoprotein levels were decreased in mice with insulin implant, in parallel with increased lipoprotein lipase activities. Atherosclerotic plaque by en face and complexity staining showed significant reductions of fat deposits and expressions of vascular adhesion molecule-1, tumor necrosis factor-α, interleukin 6, and macrophages in arterial wall while exhibiting increased activation of pAKT and endothelial nitric oxide synthase (P<0.05) comparing insulin-implanted versus sham HFD ApoE −/− mice. No differences were observed in atherosclerotic plaques between phlorizin-treated and sham HFD ApoE −/− mice, except phlorizin significantly lowered plasma glucose and glycated hemoglobin levels while increased glucosuria. Endothelial function was improved only by insulin treatment through endothelial nitric oxide synthase/nitric oxide activations and reduced proinflammatory (M1) and increased anti-inflammatory (M2) macrophages, which were inhibited by endothelial nitric oxide synthase inhibitor. 
H yperinsulinemia is associated with increased risk for cardiovascular diseases (CVDs), 1, 2 which are the major causes of morbidity and mortality among people with insulin resistance and diabetes mellitus. Hyperinsulinemia is present in systemic insulin resistance or exogenous insulin treatments. 3 The associations of systemic insulin resistance and endogenous hyperinsulinemia with elevated risk of CVDs have been consistently shown even in the absence of diabetes mellitus and hyperglycemia. 4, 5 Clinical evidence to support exogenous induced hyperinsulinemia's role to increase CVD risk is still uncertain. 6 Recent clinical studies suggest exogenous treatment with long acting insulin did not increase CVD events; yet, other studies indicated that improved glycemic control with insulin in type 2 diabetes mellitus did not reduce CVD events. [7] [8] [9] Experimentally, insulin at physiological and hyperinsulinemic levels can induce many actions on the vasculature which may have both anti-and proatherogenic effects. 10, 11 Insulin's potential antiatherogenic effects include activating endothelial nitric oxide synthase (eNOS) and regulating the expressions of vascular adhesion molecule-1 12 (VCAM-1) and antioxidant enzymes heme oxygenase-1. [12] [13] [14] The proatherogenic actions of insulin may involve the expressions of PAI-1 (plasminogen activator inhibitor-1), endothelin-1, and the migrations and proliferation of smooth muscle cells. [15] [16] [17] Previously, we reported that inhibition of insulin's actions by deleting insulin receptors on the endothelial cells accelerated atherosclerosis whereas its enhancement with IRS-1 (insulin receptor substrate-1) expression prevented or delayed the development of atherosclerosis. 12, 18 Furthermore, the induction of endogenous hyperinsulinemia in a mouse model of heterogeneous global deletion of insulin receptor did not alter the atherosclerotic process. 19 The present study characterized the effect of exogenous insulin to induce hyperinsulinemia and determined its effect in a mouse model of atherosclerosis. Furthermore, we determined whether the normalization of hyperglycemia alone, using sodium glucose cotransporters 1 and 2 (SGLT(1/2)) inhibitor, in the presence of endogenous hyperinsulinemia, can also affect the atherosclerotic process.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. ) and insulin-implanted ApoE −/− mice, fed on HFD for 16 weeks, increased body weights greater than regular diet (RD)-control mice (1.8-fold), similarly (P<0.01; Figure 1A ). Systemic insulin resistance as assessed by IPITT (intraperitoneal insulin tolerance test) was elevated equally by HFD in ApoE −/− or insulin-implanted ApoE −/− mice compared with RD-fed mice ( Figure 1B ; P<0.05). No differences were observed between sham-control and insulin-implanted ApoE −/− mice on HFD in fat distribution which was increased versus RD-fed mice ( Figure IA in the online-only Data Supplement). However, insulin-implanted HFD ApoE −/− mice exhibited significant lowered fasting plasma glucose ( Figure IB in the online-only Data Supplement; 87 versus 205 mg/dL), respectively, elevated fasting plasma insulin (2.6-fold), and IGF-1 (insulin-like growth factor-1) levels (2.7-fold) compared with control ApoE −/− mice fed on HFD at 16 weeks ( Figure 1C ; Figure IC in the online-only Data Supplement). However, insulin-treated HFD ApoE −/− mice showed reduction in plasma cholesterol levels by 33% (P<0.05) but had similar triglyceride levels compared with ApoE −/− mice on HFD ( Figure II in the online-only Data Supplement).
Results

Effect of Exogenous Hyperinsulinemia on
The severity and complexity of atherosclerotic lesions in the aortic roots and descending aorta were analyzed by multiple methods. 20 After 16 weeks, Sudan IV en face staining in HFD sham-treated mice was increased by 6.7-fold (P<0.001) ( Figure 1D ) and by 5-fold (P<0.0001) in insulin-implanted HFD versus RD-fed controls. However, the extent of fatty lesions was decreased by 20% (P<0.05) in insulin-implanted compared with sham-treated HFD-fed ApoE −/− mice ( Figure 1D ). Analysis of serial sections throughout the aortic root showed that insulin-implanted ApoE −/− mice exhibited a significant reduction in lesion area stained for collagen (Trichrome; 15%; P<0.05) and macrophage content (MAC2; 26%; P<0.05) compared with sham-treated ApoE −/− mice on HFD ( Figure 1E and 1F), but no difference was observed in smooth muscle cell content. The protein expression of VCAM-1 levels, a marker for atherosclerosis and downregulated by insulin, 12, 18, 21 was increased in the aorta of HFD-ApoE −/− mice by 307±47% versus RD-fed mice (P<0.01; Figure 1G ), which was reduced in the insulin-implanted ApoE −/− mice by 37% (P<0.01) versus HFD-sham ApoE −/− mice ( Figure 1H ).
Effect of Lowering Glucose Levels by Phlorizin
To determine the effect of lowering plasma glucose on the extent of atherosclerosis, the action of SGLT (1/2), phlorizin was studied ( Figure III in the online-only Data Supplement). Glycated hemoglobin (hemoglobin A1c) and albumin levels in the plasma from HFD-ApoE −/− mice ( Figure 2A ) were decreased by treatments with insulin or phlorizin equally (P<0.05) compared with HFD sham-treated mice, almost to the levels of RD mice. However, urinary glucose was increased only in phlorizintreated ApoE −/− mice compared with other groups of ApoE −/− mice fed on HFD ( Figure 2B ). There were no differences in the body weights between phlorizin-treated or untreated HFDApoE −/− mice although insulin-treated ApoE −/− mice weighed slightly more than other 2 groups of mice ( Figure IV in the online-only Data Supplement). IP-GTT (intraperitoneal glucose tolerance test) showed HFD treatment increased plasma glucose to >400 mg/dL at 30 minutes indicating mild diabetes mellitus. The incremental area under the curve and plasma glucose peak levels from insulin-implanted and phlorizin-treated ApoE −/− mice at both 1 and 2 hours were half as those in the HFD-sham-treated ApoE −/− mice (P<0.001; Figure 2C ). After adding either sham or phlorizin in drinking water 8 weeks after the initiation of HFD, the extent of the atherosclerosis by Sudan IV en face assessment, macrophage and collagen content, and plaque necrosis in the aortic root did not differ in HFD-ApoE −/− mice ( Figure 2D-2G) . However, the severity of atherosclerosis and necrosis was significantly decreased in the insulin-treated ApoE −/− mice (P=0.039, P=0.017, respectively; Figure 2D 
Effect on Plasma Lipoproteins and Inflammatory Cytokines
Changes in lipoprotein levels were studied, 18, 22 and no significant difference in total plasma cholesterol and triglyceride levels between phlorizin-treated or sham-treated HFD-ApoE Representative examples and quantification of cross-sections from the aortic sinus stained with trichrome (E) and MAC2 (F). G and H, Immunoblot and densitometry of vascular adhesion molecule-1 (VCAM-1) levels in aorta from control, insulin-treated, and phlorizin-treated ApoE −/− mice fed on HFD. All data are presented as mean±SEM. *P<0.05, **P<0.01. P values for panels A-C were computed using linear mixed effects models to account for the repeated measures within animals over time. P values for panels D, E, F, and H were computed using general linear model (ANOVA). In all cases, post hoc t tests with Tukey adjustment for multiple comparisons were conducted where overall F tests were significant to ascertain the location of any significant pairwise differences.
Proinflammatory cytokines, interleukin 6 (IL6), and tumor necrosis factor-α levels in the plasma and aorta were reduced in insulin-implanted ApoE −/− mice by 42% and 38%, respectively (P<0.001), compared with sham-treated ApoE −/− treated A mice. [23] [24] [25] Phlorizin-treated HFD-ApoE −/− mice did reduce plasma IL6 and tumor necrosis factor-α levels although their levels trended lower ( Figure 3D and 3E) . Expressions of Il6, Tnfα, and Vcam-1 mRNA levels in the aortic roots were also elevated in HFD sham-treated ApoE −/− mice compared with RD-fed mice, but they were not reduced in phlorizintreated HFD-ApoE −/− mice ( Figure 3F and 3G) . Interestingly, Akt activations (pAkt) were significantly increased in ) and insulin-treated ApoE −/− mice with feeding HFD. B, Fasting plasma and urinary glucose measurements from control and insulin-or phlorizin-treated HFD-ApoE −/− mice. C, Glucose tolerance test (IP-GTT [intraperitoneal glucose tolerance test]; n=8 for control, insulin treatment, and phlorizin treatment). D, Oil Red O staining (top) and quantification (bottom) of aortas as percent of lesion area from the same condition as A-C (n=11 per group). E, Quantification of cross-sections from the aortic sinus stained for collagen (top) and macrophages (bottom). F, Representative sections of hematoxylin and eosin-stained aortic root sections and quantification of necrotic area in a subgroup of 6 control lesions, insulintreated lesions, and phlorizin-treated lesions with statistically identical lesion area. All data are presented as mean±SEM. *P<0.05, **P<0.01. P values for panels A and C were computed using linear mixed effects models to account for the repeated measures within animals over time. P values for panels B, D, E, F, and G were computed using general linear model (ANOVA). In all cases, post hoc t tests with Tukey adjustment for multiple comparisons were conducted where overall F tests were significant to ascertain the location of any significant pairwise differences.
insulin-implanted versus HFD sham-treated and phlorizintreated ApoE −/− mice (Figure 3H and 3I ; P<0.01, P<0.01, P<0.01) respectively. Because nitric oxide (NO) can be induced by insulin and pAkt, 26 we assessed the activation of eNOS in the aorta, which were increased in insulin-implanted ApoE −/− compared with phlorizin-treated and sham-treated HFD ApoE −/− mice (Figure 3J and 3K ; P<0.01).
Changes in Circulating and Tissue Monocytes and Macrophages Polarization
Similar to previous reports, [27] [28] [29] [30] −/− mice (n=6, respectively). C, Pooled plasma samples were subjected to fast performance liquid chromatography gel-filtration, and the fractions were assayed for cholesterol concentration. Tumor necrosis factor-α (TNF-α; D) and interleukin 6 (IL6; E) plasma levels from all ApoE −/− mice. The gene expressions of the inflammatory markers Il6 mRNA (F) and Tnfα mRNA (G) were measured in pooled aortic arch from all ApoE −/− mice. H and I, Immunoblot and densitometry of Akt and Erk activity and vascular adhesion molecule-1 (VCAM-1) levels in aorta from all ApoE −/− mice. J and K, Immunoblot and densitometry of endothelial nitric oxide synthase (eNOS) activity in aorta from all ApoE −/− mice. All data are presented as mean±SEM and representative of 3 independent experiments. *P<0.05, **P<0.01. P values were computed using general linear model (ANOVA). Post hoc t tests with Tukey adjustment for multiple comparisons were conducted where overall F tests were significant to ascertain the location of any significant pairwise differences. ) cell surface markers showed HFD increased M1 proinflammatory macrophages and decreased M2 anti-inflammatory macrophages in the aorta. In contrast, exogenous insulin treatment shifted the macrophage population away from M1 toward M2 subtype, but phlorizin was ineffective ( Figure 4B ). In addition, insulin treatment decreased the expression of Ccr7, Cxcl10, and iNos in M1 macrophages ( Figure 4C ) and increased M2-related genes, such as Arg1, Ccl17, and Cd206 ( Figure 4D ). To identify the source of circulating tumor necrosis factor-α and IL6, gene expressions of Tnfα and Il6 in white adipose tissue and brown adipose tissues from the HFD-ApoE −/− mice were studied. Tnfα and Il6 mRNA expressions in subcutaneous white adipose tissue were inhibited by exogenous insulin treatment but not by phlorizin treatment ( Figure IX in the online-only Data Supplement). In addition, MAC2-DAB + and F4/80 + immunostaining macrophages (M1) were abundant in subcutaneous white adipose tissue from both HFD-ApoE −/− mice in the absence or presence of phlorizin treatment, but they were decreased in insulin-treated HFD-ApoE −/− mice ( Figure 4E ). Flow cytometry showed that M1 subtypes were reduced and M2 subtypes were increased in stromal vascular fraction cells isolated from exogenous insulin-treated HFD-ApoE −/− mice compared with other groups of mice ( Figure 4F ).
Endothelial Function and eNOS/NO Signaling on M1/M2 Polarization
To determine directly whether NO can affect M1/M2, NO donor, S-nitrosoglutathione was added to THP-1 cells in the presence and absence of lipopolysaccharides (LPS) and interferon-γ. Fluorescence-activated cell sorting analysis showed that LPS/ interferon-γ treatment increased CD80 + /CD206 − subpopulation, which were inhibited only by S-nitrosoglutathione while insulin or phlorizin's have no effect (Figure 5A-5C ). Moreover, quantitative reverse transcription polymerase chain reaction analysis of proinflammatory genes (Tnfα and Il6) and M1-polarized genes (iNos and Ccr7) expression also supported that S-nitrosoglutathione inhibits LPS/interferon-γ-mediated inflammation and increased in M2 polarization ( Figure 5D and 5E). To explore the relationship between endothelial eNOS/NO signaling and changing M1 and M2 phenotype, we cocultured primary lung endothelial cells from ECIRS1 mice that exhibited increased Akt/eNOS signaling and enhanced NO production with THP-1 cells Figure 5F-5H) . However, the addition of an inhibitor of eNOS activities, l-NAME (N ω -nitrol-arginine methyl ester) attenuated the decrease M1 and increase in M2 polarization, suggesting that enhancing eNOS/NO activity in endothelial cells can decrease M1/M2 ratio in the aorta (Figure 5F-5H ).
Discussion
Hyperinsulinemia because of either endogenous origin, such as insulin resistance, or exogenous sources as in insulin therapy has been implicated clinically to enhance the development of atherosclerosis. 5, 31, 32 Previously, we have reported that the severity of atherosclerosis was not affected by endogenously induced hyperinsulinemia in the absence of systemic insulin resistance. 19 In contrast, we reported here that the effect of exogenously applied insulin decreased the severity of atherosclerosis in ApoE −/− mice on HFD which generated hyperinsulinemia, insulin resistance, and hyperglycemia. Unlike the endogenously generated hyperinsulinemic ApoE −/− model, the present study was performed in ApoE −/− mice on HFD which induced weight gain, insulin resistance, elevated levels of abdominal and visceral fat, hyperglycemia, and hyperinsulinemia, which were elevated further (2×) by insulin implants. The implanted insulin improved glucose tolerance tests and significantly increased IGF-1 levels but did not affect weight gain or fat mass. The inability of endogenously derived hyperinsulinemia to affect the atherosclerosis in ApoE −/− mice with insulin receptor partial deletion, as reported previously, suggests that doubling of plasma insulin levels were not adequate to affect the atherosclerotic process. 19 The elevation of IGF-1 levels was unlikely to affect the atherosclerotic process because the IGF-1 levels attained by insulin treatment only returned them to normal and physiological levels.
Because multiple metabolic parameters were changed with the insulin implant, because of the metabolic actions of hyperinsulinemia, the explanation for the decrease in atherosclerosis is likely to be complex. Major differences induced by the exogenous insulin implants compared with endogenous induced hyperinsulinemia were lowering of plasma glucose, lipoproteins, and inflammatory markers. To test whether the singular effect of glycemic control by implanting insulin in this insulin resistant and diabetic model can affect atherosclerosis, glycemic control was improved using phlorizin, a selective inhibitor of SGLT(1/2), which enhanced glycosuria, decreased hemoglobin A1c, and glycated albumin, without changes in lipoprotein profile. 33, 34 Interestingly, lowering plasma glucose alone did not affect the severity of atherosclerosis in the HFDfed ApoE −/− mice model. These results suggest that normalizing plasma glucose alone without decreasing fat composition and altering inflammatory process was inadequate to affect the atherosclerosis process in insulin resistance and diabetes mellitus. These findings in the ApoE −/− mice are consistent with clinical trials that have shown glycemic control alone may not decrease CVD in people with type 2 diabetes mellitus.
2,7-9 Our study supports Yoon et al 35 who showed that chronic insulin treatment has beneficial effects on dyslipidaemia, IL6 levels, and atherosclerosis in Ldlr −/− mice with diet-induced obesity and diabetes mellitus.
Recently, EMPA-REG OUTCOME study (Multicenter Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial) reported that SGLT2 inhibitor treatment reduced cardiovascular mortality and heart failure in patients with type 2 diabetes mellitus although the incidence of fatal/ nonfatal myocardial infarction and nonfatal stroke was not changed. This indicates that the beneficial effect of SGLT2 inhibitor was driven by improvement in the myocardial function, which occurred after a few months of treatments 36, 37 rather than reversing atherosclerotic lesion, which will require years to occur. 38 Contrary to our study, Nagareddy et al 39 has reported that lowering glucose levels by SGLT2 inhibitor decreased + macrophages. C and D, M1 (Ccr7, Cxcl10, and iNos) and M2 (Arg1, Ccl17, and Cd206) genes expression in aorta. Data show % in gene expression by quantitative reverse transcription polymerase chain reaction. E and F, Representative DAB (3'-diaminobenzidine) and immunostaining (E) and quantification (F) of adipose tissue macrophages in subcutaneous white adipose tissue (scWAT). G, FACS analysis shows staining of CD80 or CD206 in the stromal vascular fraction of scWAT from these mice. Results are pooled from 3 independent experiments with 2 to 5 mice per group. All data are presented as mean±SEM and representative of 3 independent experiments. *P<0.05, **P<0.01. P values were computed using general linear model (ANOVA). Post hoc t tests with Tukey adjustment for multiple comparisons were conducted where overall F tests were significant to ascertain the location of any significant pairwise differences.
diabetes mellitus-induced monocytosis and myelopoiesis in streptozotocin-induced diabetic and Akita mice and decreased atherosclerotic lesions in streptozotocin-induced Ldlr −/− mice. However, their study differed significantly from our study because streptozotocin-or Akita-induced diabetes mellitus are insulin-deficient models whereas our ApoE −/− mice have hyperinsulinemia and mild diabetes mellitus due HFD (60%), which mimics type 2 diabetes mellitus. 40 Another potential antiatherosclerotic effect of hyperinsulinemia in the HFD-fed ApoE −/− mice could be because of improvement in lipoprotein profile. Insulin implant significantly lowered very-low-density lipoprotein and low-density lipoprotein levels and decreased atherosclerosis in ApoE −/− mice. 41 Interestingly, the levels of atherosclerosis in insulin-treated ApoE −/− mice were less than those in ApoE −/− mice-fed Western diet (42% of Kcal) although there were no differences in plasma cholesterol levels − (M1) and CD80 − /CD206 + (M2). All data are presented as mean±SEM and representative of 3 independent experiments. *P<0.05, **P<0.01. P values were computed using general linear model (ANOVA). Post hoc t tests with Tukey adjustment for multiple comparisons were conducted where overall F tests were significant to ascertain the location of any significant pairwise differences. between these 2 ApoE −/− models ( Figure X in the online-only Data Supplement). Exogenous insulin implant also significantly reduced various inflammatory circulating cytokines and their expression on the aorta, including IL6, tumor necrosis factor-α, and VCAM-1. Besides the reduction of inflammatory cytokines, our results also suggested that exogenously treated hyperinsulinemia decreased macrophages in the aorta but did not affect systemic monocytosis induced by HFD. The improvements of insulin's anti-inflammatory actions are likely to be mediated via several mechanisms, such as decreasing VCAM-1 expression, activation of eNOS in the endothelial cells, and altering the M1/M2 ratio toward the anti-inflammatory profile.
In summary, this report demonstrated that exogenously induced hyperinsulinemia, even in the presence of insulin resistance, hyperglycemia, and hyperlipidemia, can decrease the severity and complexity of the atherosclerotic process. The antiatherogenic effect of the exogenously induced hyperinsulinemia is not because of the lowering of plasma glucose alone but is also related to decreasing low-density lipoprotein and very-low-density lipoprotein levels and reductions of inflammatory cytokines. The effect of insulin on improving lipid profile is probably related to its actions in the liver and the activation of lipoprotein lipase as previously reported. 42, 43 However, insulin also had significant anti-inflammatory actions of inhibiting VCAM-1 and activities eNOS in the endothelium to decrease monocyte uptake into the vascular wall and the expression of the various inflammatory actions. Clinical significance of these findings in rodent models of atherosclerosis and insulin resistance will need to be evaluated further.
